Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480594 · ClinicalTrials.gov registry record
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway
A clinical trial of Fatty Liver, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT03480594 is a study of Fatty Liver that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 22 participants, below the 210-participant average among 20 other Fatty Liver trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03480594, a study of Fatty Liver, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an imaging agent for detection of altered PDH flux in fatty liver.
Conditions Studied
Interventions
- DRUG MRI Tracer
Study Locations (1)
Texas
- Advanced Imaging Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-10-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03480594
The ClinicalTrials.gov registry entry for NCT03480594 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 20 other Fatty Liver trials with a reported enrollment target (90% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fatty Liver appearing as the primary indexed condition, and to 1 intervention - of which MRI Tracer is the first listed.
NCT03480594 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03480594 about?
NCT03480594 is a clinical study titled "Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway". The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an imaging agent for detection of altered PDH flux in fatty liver.
What is the current status of trial NCT03480594?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2018-10-01. Estimated completion is 2023-10-13.
What conditions does trial NCT03480594 study?
This clinical trial studies the following conditions: Fatty Liver.
What interventions are being tested in trial NCT03480594?
The interventions under investigation include: MRI Tracer (DRUG).
Who is sponsoring clinical trial NCT03480594?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03480594 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatty Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Early Tracking of Childhood Health Determinants (ETCHED) Study
RECRUITING
-
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
RECRUITING
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
-
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.